🟢 MEDPAL AI is trading 11.36% up today after FDA approval expands Mounjaro’s cardiovascular-risk indication

MEDPAL AI is trading 11.36% up at £4.90 after highlighting September 1, 2026 FDA approval for Mounjaro to reduce major cardiovascular risks in certain adults with type 2 diabetes.

• Company said the expanded indication could broaden GLP-1 demand beyond diabetes and weight management; New Health already dispenses Mounjaro in the UK.
• RNS-reported, the move is company-specific, not primarily sector-driven, despite broader healthcare strength.
• Shares rose from the September 1 close of £4.35 to £4.90, extending recent volatility and gains.